The founder of Care A2 Plus changed product labelling approved by regulators in the United States, delaying the delivery of baby formula, the company’s distribution partner has alleged.

In documents filed in the Federal Court, Gensco Pharma alleges it will lose more than $200 million in future profits because of the failure of the agreement. The Florida-headquartered distributor also alleges Care A2 Plus misled it when it claimed to be able to produce up to 4.9 million tins of formula per month to supply the US, which was suffering from crippling shortages following contamination at a major plant early last year.